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Abstract
INTRODUCTION: Hippocampal volume (HV), cortical metabolism, and thickness
are decreased in mild cognitive impairment (MCI). Hippocampal metabolism
(HM) studies comparing MCI and clinically normal (CN) elderly gave
inconsistent results. As hippocampus is a key region in Alzheimer's disease,
we hypothesized that HM is specifically decreased in high-amyloid MCI.
METHODS: Overall, 250 CN and 45 MCI underwent three-dimensional
magnetic resonance imaging, fludeoxyglucose-positron emission tomography,
and fluorodeoxyglucose-positron emission tomography (PET), and Pittsburgh
Compound B (PiB) PET. We investigated the interaction between clinical and
amyloid status on HM, HV, cortical metabolism, and thickness using linear
models, covarying age, gender, and education. Analyses were conducted with
and without correction for multiple comparisons and for partial volume effects.
RESULTS: Volume-adjusted HM was decreased in high-amyloid MCI but close
to normal in low-amyloid MCI and in high-amyloid...
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Abstract
INTRODUCTION—Hippocampal volume, cortical metabolism and thickness are decreased in 
mild cognitive impairment (MCI). Hippocampal metabolism studies comparing MCI and clinically 
normal (CN) elderly gave inconsistent results. As hippocampus is a key region in Alzheimer’s 
disease, we hypothesized that hippocampal metabolism is specifically decreased in high-amyloid 
MCI.
METHODS—250CN and 45MCI underwent 3D-MRI, FDG-PET, and PIB-PET. We investigated 
the interaction between clinical and amyloid status on hippocampal metabolism, hippocampal 
volume, cortical metabolism and thickness using linear models, covarying age, gender, and 
education. Analyses were conducted with and without correction for multiple comparisons and for 
partial volume effects.
RESULTS—Volume-adjusted hippocampal metabolism was decreased in high-amyloid MCI but 
close to normal in low-amyloid MCI and in high-amyloid CN. Both MCI groups had hippocampal 
atrophy, although less severe in low-amyloid MCI. High-amyloid CN and high-amyloid MCI had 
cortical hypometabolism.
DISCUSSION—Hippocampal metabolism is decreased when both cognitive impairment and 
amyloid are present.
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BACKGROUND
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder defined pathologically 
by the presence of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles [1, 2]. Over the 
past decade, PET imaging biomarkers have been developed that detect Aβ during life; and 
amyloid PET now supports a diagnosis of cognitive impairment specifically due to AD [3]. 
Elevated Aβ is commonly but not invariably detected with PET among mildly cognitively 
impaired (MCI), non-demented elderly, and when present, it confirms a diagnosis of 
prodromal MCI due to AD [4, 5]. Aβ is frequently detected with PET among clinically 
normal (CN) elderly individuals, in whom it confers increased risk of future cognitive 
decline [6, 7]. A second class of imaging biomarkers, which have evolved over many years, 
primarily detects later stage pathophysiologic changes that putatively result from the 
defining pathologies of AD. These include image measures of brain regions vulnerable to 
damage in AD, hippocampal volume (HV), thickness of the association cortex (ACT), and 
metabolism in the association cortex (ACM). These biomarkers, while much less specific for 
underlying pathology, have been useful to assess disease progression because they correlate 
with concurrent changes in cognitive and functional measures of clinical decline along the 
AD trajectory [8, 9]. Here we evaluated hippocampal metabolism (HM), after adjusting for 
hippocampal volume loss, to determine whether it was associated with both specificity of 
underlying molecular pathology, i.e., high levels of Aβ, and the cognitive phenotype that 
signified progression along the AD trajectory, i.e., MCI. We found that HM was decreased in 
MCI individuals with high Aβ, but not in low Aβ MCI or in CN.
METHODS
1. Participants: see Table 1
Two hundred ninety-five non-demented participants from the Harvard Aging Brain Study 
and other ongoing studies on aging and AD were analyzed in the present report. We utilized 
criteria from the Alzheimer’s Disease Neuroimaging Initiative (ADNI2) to classify 
participants either as clinically normal (CN) older adults or as patients with amnestic mild 
cognitive impairment (MCI), single- or multiple-domain. The Logical Memory (LM) IIa of 
the Wechsler Memory Scale–Revised (delayed recall) was used to assess objective memory, 
using an education adjusted cut-off, as described previously [6]. MCI patients and/or study 
partner reported a memory complaint, but had essentially intact activities of daily living, as 
assessed by the Functional Activities Questionnaire and Clinical Dementia Rating (CDR), 
and no evidence of dementia [10]. Criteria for MCI (n=45) included a global CDR score of 
0.5, a Memory Box score ≥ 0.5 and an education-adjusted Mini-Mental State Examination 
(MMSE) ≥24. Criteria for CN (n=250) included a global CDR score of 0, an education-
adjusted MMSE score ≥27 and an education-adjusted LM performance within the normal 
range (≥9 for ≥16y, ≥7 for 8–15y and ≥5 for <8y of education). All participants were 
medically stable and did not have confounding neurological or psychiatric conditions or 
substance or alcohol abuse within the past 2 years. All MCI patients had a Modified 
Hachinski Ischaemic Score ≤ 4 and a Geriatric Depression Scale (long form) ≤10. Written 
informed consent was obtained prior to experimental procedures and the study was 
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approved, and conducted, in accordance with the Partners Human Research Committee at 
the Massachusetts General Hospital and Brigham and Women Hospital (Boston, MA).
2. Brain imaging procedures
Structural MRI, FDG-PET and PIB-PET images were acquired within one year for each 
subject. Median delay between imaging sessions was 39 days (min: 0 – max: 302).
MRI data were collected on a Siemens TrioTim 3 tesla scanner equipped with a 12-channel 
phased-array head coil. High-resolution T1-weighted anatomical images were acquired 
using an MPRAGE with the following parameters: repetition time =6400ms, echo time 
=2.8ms, inversion time =900ms, 8° flip angle, sagittal slides, voxel size=1.0×1.0×1.2mm. 
MRI data were analyzed in the native space using Freesurfer version 5.1 (http://
surfer.nmr.mgh.harvard.edu), including estimation of HV and cortical thickness. Freesurfer 
output files (brainmask.mgz) were individually assessed and manual interventions included 
examination of the white and pial surface segmentation. In cases where dura or skull 
influenced the segmentation result, voxels were either manually edited or corrected by 
adjusting the watershed threshold. In cases where the grey matter ribbon clearly included 
white matter or clearly excluded grey matter; control points were added to the recon and/or 
white matter edits were made to the wm.mgz file. Autorecon2 and autorecon3 processing 
steps were re-run on the edited files. HV was collapsed across hemispheres and adjusted for 
total intracranial volume (ICV) using the following equation: Adjusted HV = Raw HV − b * 
(ICV − Mean ICV), where b indicates the regression coefficient when HV is regressed 
against ICV and mean ICV is the average ICV value of CN older adults.
FDG-PET data were acquired as described previously [11]. A bolus of 5 mCi of 18F-FDG 
was injected, in a quiet, dimly lit room, with subjects in the eyes-open state. FDG 
acquisition began 45 minutes (min) after injection and lasted 30 min. Each individual PET 
data set was rigidly co-registered to the subject’s MRI data. The cortical ribbon and 
subcortical Freesurfer ROIs defined by MRI as described above were transformed into the 
PET native space using SPM8. FDG was expressed as the standardized uptake value and 
normalized to the cerebellum gray matter for each ROI. A hippocampal ROI was compared 
to an association cortex ROI. Association cortex was defined as an aggregate of regions 
known to be affected in MCI [12]: bilateral precuneus, inferior parietal and inferior temporal 
cortices. We used two methods to take into account the impact of the underlying anatomy on 
FDG: First, the corresponding structural data (HV for HM and ACT for ACM) were used as 
covariates in the FDG analyzes. Second, we used a geometric transfer matrix method [13] to 
correct FDG data for partial volume effects (PVE), as shown in the supplementary graphs.
PIB was synthesized, and PIB-PET data were acquired as described previously [14]. A bolus 
of 10–15 mCi of 11C-PiB was injected and followed immediately by a 60-min dynamic 
acquisition, using a HR+ PET camera (3D mode; 63 image planes). PIB data were 
reconstructed with ordered set expectation maximization, corrected for attenuation. Each 
frame was evaluated to verify adequate count statistics and absence of head motion. Using 
Logan’s graphical analysis method [15], we calculated PIB retention expressed as the 
distribution volume ratio (DVR), using a gray matter cerebellum reference region. Aβ status 
was determined for each subject using a global DVR from a set of neocortical regions 
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including frontal, lateral temporal, lateral parietal and retrospenial cortex (the FLR region). 
Participants were classified as either low- Aβ or high-Aβ, based on a threshold of 1.20, as 
described previously [6]. Four groups of interest were defined: low-Aβ CN (n=188), high-
Aβ CN (n=62), low-Aβ MCI (n=24) and high-Aβ MCI (n=21).
3. Statistical analyses
For each variable of interest (HM, HV, ACM and ACT), we fit a linear model investigating 
the interaction between clinical and Aβ status, covarying age, gender, education, and 
structural data (HV for HM, ACT for ACM). We computed post-hoc tests (Table 2) to 
compare each pairwise group comparison, adjusting for multiple comparisons (family-wise 
error correction using Tukey’s Honest Significant Difference test). In order to avoid rejecting 
a difference that might be present, we also report uncorrected p-values from these models 
(Fischer’s Least Significant Difference test). We additionally analyzed the correlations 
between imaging and cognitive (MMSE) data and computed ROC curves to investigate 
sensitivity and specificity of each biomarker to detect (1) MCI among CN, and (2) elevated 
Aβ among MCI. Statistical analyses were conducted in Statistica version 13 (Statsoft, Dell). 
We report two-tailed p-values.
RESULTS
1. Hippocampal metabolism: (Graph 1.A, supplementary Graph S1 for PVE-corrected data)
The interaction between clinical diagnosis and Aβ was significant (unstandardized β-
estimate =.16, p=.029). Age (β=.06, p=.322), gender (β=−.01, p=.811) and education (β=.
01, p=.846) were not related to HM. Yet, HV was associated with HM (β=.15, p=.025). 
PVE-corrected data gave similar results although HM was negatively associated with HV 
(β=−.16, p=.013), possibly due to an over-correction. Post-hoc tests showed that high-Aβ 
MCI had significantly lower HM than any other group. Low-Aβ MCI and high-Aβ CN did 
not demonstrate reduction in HM, even using a liberal uncorrected threshold (see Table 2).
2. Hippocampal volume: (Graph 1.B)
The interaction between clinical diagnosis and Aβ was significant (β=.13, p=.045). Older 
ages (β=.37, p<.0001) were significantly associated with reduced HV while gender (β=.07, 
p=.180) and education (β=.04, p=.478) were not. Post-hoc tests showed that high-Aβ MCI 
had significantly lower HV than any other group but high-Aβ CN and low-Aβ MCI also had 
hippocampal atrophy, compared to low-Aβ CN.
3. Association cortex metabolism: (Graph 1.C, supplementary Graph S2 for PVE-corrected 
data)
The interaction between clinical diagnosis and Aβ was significant (β=.17, p=.013). Older 
ages (β=.15, p=.007) and male gender (β=.19, p=.0005) were significantly associated with 
lower ACM while education (β=.07, p=.195) and cortical thinning (β=.05, p=.373) were not. 
PVE-corrected data gave similar results although ACM was negatively associated with ACT 
(β=−.15, p=.006). Post-hoc tests showed that high-Aβ MCI had significantly lower ACM 
than any other group. High-Aβ CN also demonstrated reduced ACM compared to low-Aβ 
CN; however, ACM was not different in low-Aβ MCI and low-Aβ CN.
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4. Association cortex thickness: (Graph 1.D)
The interaction between clinical diagnosis and Aβ failed to reach significance (β=.10, p=.
171). Older ages (β=.17, p=.0004) were associated with lower ACT while gender (β=.03, 
p=.583) and education (β=.10, p=.076) were not. Post-hoc tests showed that high-Aβ MCI 
had significant cortical thinning compared to low-Aβ CN and, to a lower extent, compared 
to the other groups. High-Aβ CN had slight thinning, that did not survive after correction for 
multiple comparisons.
5. Correlations between cognition and imaging: (Graph 2) – adjusted for age, gender, 
education, and structural data for HM and ACM. CN and MCI are pooled for this analysis
In low-Aβ subjects—MMSE correlated with HV (r=.14, p=.048) and with ACT (r=.26, 
p<.001). In contrast, MMSE did not correlate with HM (r=−.01, p=.860) nor with ACM (r=.
04, p=.605). Similar results were found using PVE-corrected data (HM: r=.04, p=.527, 
ACM: r=.03, p=.622).
In high-Aβ subjects—MMSE correlated with HV (r=.29, p=.010), HM (r=.27, p=.015) 
and ACM (r=.30, p=.007). In contrast, ACT did not correlate with MMSE (r=.06, p=.619). 
Similar results were found using PVE-corrected data (HM: r=.31, p=.006, ACM: r=.29, p=.
008).
Interactions—The interaction between Aβ status and MMSE in the model for HM was 
significant (p=.026) but not in the model for HV (p=.527), ACM (p=.104), or ACT (p=.067, 
in the opposite direction: MMSE predicts ACT in low- but not in high-Aβ). PVE-corrected 
data gave similar results (supplementary graph S3) but the interaction between MMSE and 
PiB status in the model for HM (p=.086) and ACM (p=.106) were both slightly above the 
threshold for significance.
6. Sensitivity and specificity of imaging markers: Receiver Operating Characteristic (ROC) 
curves and area under the curve (AUC) analyses were adjusted for age, gender, and 
education
Hippocampal markers had higher AUC than cortical markers for discriminating MCI from 
CN (Graph 3.A), although the difference only reached statistical difference between HV and 
ACT (p=.009; HV-ACM: p=.169; HM-ACM: p=.304; HM-ACT: p=.212). In contrast, FDG 
markers had higher AUC than MRI markers for discriminating high-Aβ MCI from low-Aβ 
MCI (Graph 3.B), but without reaching statistical significance (all p>.200).
All biomarkers discriminated high-Aβ MCI from CN (Graph 4.A) and were significantly 
better for doing so than for discriminating low-Aβ MCI from CN (p<.050, DeLong test). 
Only HV significantly discriminated low-Aβ MCI from CN (Graph 4.B); the AUC for the 
other markers were not significantly greater than 0.5.
DISCUSSION
This report investigated four AD biomarkers using two imaging modalities: structural MRI 
and FDG-PET and focused on two areas of interest: the hippocampal formation and the 
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association cortex. The main finding is that hippocampal hypometabolism is only 
observed when cognitive impairment and Aβ are both present. Below we discuss the 
results in the context of other studies of volumetric and metabolic alterations occurring in 
MCI and high-Aβ CN.
1. Biomarkers in MCI
In this study, we found that HM was reduced in MCI compared to CN, in accordance with 
several previous reports [16–19]; but other studies did not find hippocampal 
hypometabolism in MCI [20–23]. However, previous studies focused on HM in MCI did not 
directly compare high- and low-Aβ MCI versus CN [24–26]. We observed that HM was 
only decreased in high-Aβ MCI, not in low-Aβ MCI. Aβ status may at least partially explain 
the discrepancies between previous studies, as these studies may differ in their relative 
number of low- and high-Aβ MCI. The present report confirms a previous one [17] 
highlighting “the crucial relevance of using reference-region-based scaling, and the higher 
sensitivity of PVE-corrected PET measures, to detect hippocampal hypometabolism in 
MCI” although we could also demonstrate reduced HM using FDG-PET data uncorrected 
for PVE. We found that HM correlated with HV, but the observed effects were still present 
after volume adjustment or partial volume correction (see supplementary graphs), showing 
that the hippocampal hypometabolism in high-Aβ MCI does not merely reflect gross 
hippocampal atrophy.
FDG values observed in low-Aβ MCI were close to normal, suggesting that metabolism is 
specifically decreased by Aβ, as shown in previous FDG work [26–28]. Other studies 
reported either decreased [29] or increased [30] ACM in low-Aβ MCI, indicating that this is 
likely a heterogeneous condition. Without further describing the pathological substrates 
observed in these patients, and looking more selectively at specific regions of interest 
according to the pathology, HM and ACM do not appear suitable to diagnose low-Aβ 
amnestic MCI. Other MTL pathologies, such as TDP-43 or hippocampal sclerosis, might 
differentially affect HV and HM [31], but in-vivo images of these pathologies are not yet 
available.
In the present results, ACM and HM were significantly associated with cognitive measures 
in the high-Aβ but not in the low-Aβ participants. In other words, FDG only decreases with 
cognition when cognitive impairment is due to Aβ. Noteworthy, HM did not correlate with 
any of the demographic data (and not with age in particular) unlike the other biomarkers we 
studied. This may contribute to the specificity of this biomarker for cognitive impairment 
and AD pathology. Previous studies showed that HM was lower in MCI that will 
subsequently decline than in non-decliners MCI [26, 32]. This is consistent with our results 
given the higher risk of decline among the MCI with elevated Aβ [33, 34] and is another 
argument for the high specificity of HM for symptomatic AD.
We observed that high-Aβ MCI had smaller HV than low-Aβ MCI, a finding consistent with 
other studies [35, 36] and the link between hippocampal atrophy with the risk of evolving to 
AD dementia [37, 38]. HM, ACM and HV all discriminated high-Aβ MCI from CN equally 
well, and more generally MCI from CN. But low-Aβ MCI also had hippocampal atrophy, 
although to a lower extent. Cognitive measures correlated with HV in participants with high-
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Aβ and with low-Aβ. HV also correlated with age. HV therefore appears to be less specific 
for AD pathology than HM or ACM but more sensitive to aging and potentially to other non-
AD disorders. ROC curves confirmed that HV is highly discriminant for cognitive 
impairment but not as much for Aβ pathology. Cognitive follow-up of low-Aβ MCI with 
hippocampal atrophy is of particular interest as this may constitute an important risk for 
further cognitive decline [29].
As reported previously [39, 40], high-Aβ MCI have decreased ACT when compared to low-
Aβ CN. However, ACT was less discriminant for high-Aβ MCI than the other biomarkers 
we studied. As it was shown for HV, ACT correlated with age, and with cognition in low-Aβ 
subjects, likely capturing decline related to non-AD pathology. We did not find decreased 
ACT in low-Aβ MCI although other groups have found cortical thinning in this population 
[41]. Of note, they found thinning in the left medial prefrontal and right anterior temporal 
cortices, regions that were not included in our ACT ROI that we choose to match the ACM 
ROI used in FDG-PET.
Overall, the four studied biomarkers proved to be more altered in high-Aβ MCI than in any 
other groups, arguing that this population is most probably at the prodromal stage of AD.
2. Biomarkers in high-Aβ CN
Both HV and ACM were significantly decreased in high-Aβ CN when compared to low-Aβ 
CN. In contrast, volume-adjusted HM was normal in high-Aβ CN, suggesting that decreased 
glucose metabolism in the medial temporal lobe may be a specific marker of cognitive 
impairment due to AD and not only a marker of Aβ. Unlike ACM, where associations with 
Aβ are observable in the preclinical stage of the disease [28], HM appears to be sensitive to 
the combination of Aβ and cognitive impairment. Similar observations have been made in 
functional MRI studies: alterations in hippocampal activity seem to arise in prodromal but 
not in preclinical AD [36]. The operationalization of the diagnostic criteria for preclinical 
AD proposes to use HV and ACM to define neurodegeneration (ND) [42]. Our data 
highlights an important limitation of this operationalization: the FDG signal in hippocampus 
may differ from that in neocortex, and from HV; thus indicating that not all ND has the same 
biological relevance, some ND is more specific for Aβ than other, and some ND is more 
specific for cognitive impairment. From this study, it appears that HM only decreased when 
both conditions are met. This might be interesting properties for tracking disease 
progression.
CONCLUSION
This study provides evidence of hippocampal hypometabolism in prodromal AD, together 
with other metabolic and structural alterations. Low-Aβ MCI demonstrated hippocampal 
atrophy, although to a lower extent. In contrast, FDG only decreased in the presence of Aβ: 
in the neocortex before; and in the hippocampus after cognitive impairment has occurred. 
HM could therefore be an interesting outcome for tracking disease progression. These cross-
sectional results motivate a longitudinal study of HM in high-Aβ CN to determine whether 
this feature will predict progression to MCI due to AD.
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Research in context
SYSTEMATIC REVIEW
The authors reviewed the literature using PubMed and the keywords: “amyloid”, 
“hippocampus”, “FDG”, and “mild cognitive impairment (MCI)”. Hippocampal volume 
and association cortex metabolism are largely used as neurodegenerative markers in 
various AD stages. However, hippocampal metabolism in MCI is still a matter of debate. 
Hippocampal metabolism in low- and high-amyloid MCI still needs to be investigated. 
These relevant citations are appropriately cited.
INTERPRETATION
Our findings led to a decrease in hippocampal metabolism in high-amyloid MCI that is 
not present in low-amyloid MCI. Unlike cortical metabolism or hippocampal volume, 
hippocampal metabolism was normal in high-amyloid clinically normal elderly, making 
it a potential useful marker for tracking disease progression.
FUTURE DIRECTIONS
The manuscript discusses the findings in the context of other volumetric and metabolic 
studies. These cross-sectional results motivate a longitudinal study of hippocampal 
metabolism to determine whether this feature in normal elderly will predict progression 
to MCI.
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Graph 1. 
Imaging data in clinically normal (CN) and mild cognitive impairment (MCI), adjusted for 
covariates
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Graph 2. 
Scatterplot of hippocampal metabolism against MMSE, categorized by amyloid status
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Graph 3. 
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Graph 4. 
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TABLE 1
Demographic, cognitive and amyloid data for clinically normal (CN) older adults and patients with mild 
cognitive impairment (MCI), categorized by amyloid status (Aβ)
Mean +/− standard deviation Low-Aβ CN High-Aβ CN Low-Aβ MCI High-Aβ MCI
Number of participants 188 62 24 21
Age (years) 73.2 +/− 5.9 75.4 +/− 6.2* 71.8 +/− 7.5 73.3 +/− 8.4
Gender (% of male) 39.3% 41.9% 62.5%* 61.9%*
Education (years) 15.8 +/− 3.0 16.2 +/− 2.8 15.8 +/− 3.3 16.9 +/− 2.4
Clinical Dementia Rating 0 0 0.5 0.5
Mini-Mental State Exam 29.1 +/− 1.0 28.8 +/− 1.0 27.8 +/− 1.4** 27.0 +/− 2.0**
Logical Memory delayed recall 14.4 +/− 3.4 14.0 +/− 3.0 7.4 +/− 3.3** 6.3 +/− 5.2**
Aβ (neocortical PIB DVR) 1.08 +/− 0.05 1.42 +/− 0.15** 1.08 +/− 0.06 1.60 +/− 0.17**
*Significantly different from low-Aβ CN (p<.050)
**(p<.001)
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